Patients with moderate to severe plaque psoriasis: One year after the European medicines agency recommendation of efalizumab suspension

Dermatology

Volumn 222, Issue 3, 2011, Pages 250-255

  Talamonti, M ^a   Teoli, M ^a   Botti, E ^a   Spallone, G ^a   Chimenti, S ^a   Costanzo, A ^a  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

Efalizumab; Progressive multifocal leukoencephalopathy; Psoriasis; Psoriasis Area and Severity Index; Rebound

Indexed keywords

ADALIMUMAB; CORTICOSTEROID; CYCLOSPORIN; EFALIZUMAB; ETANERCEPT; INFLIXIMAB; METHOTREXATE;

ADULT; AGED; ARTICLE; BIOLOGICAL THERAPY; DISEASE SEVERITY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PRESCRIPTION; PRIORITY JOURNAL; PSORIASIS SEVERITY INDEX; PSORIASIS VULGARIS; SYSTEMIC THERAPY; TREATMENT OUTCOME;

ADULT; AGED; ANTIBODIES, MONOCLONAL; BIOLOGICAL PRODUCTS; CYCLOSPORINE; DERMATOLOGIC AGENTS; FEMALE; HUMANS; MALE; METHOTREXATE; MIDDLE AGED; PSORIASIS; SAFETY-BASED DRUG WITHDRAWALS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; WITHHOLDING TREATMENT; YOUNG ADULT;

EID: 79960016306     PISSN: 10188665     EISSN: 14219832     Source Type: Journal    
DOI: 10.1159/000326111     Document Type: Article

References (35)

1. Bos JD, De Rie MA: The pathogenesis of pso-riasis: immunological facts and specula-tions. Immunol Today 1999; 20:40-46. (Pubitemid 29136549)
2. Gottlieb AB: Product development for pso-riasis: clinical challenges and opportunities; in Roenigk HH Jr, Maibach HI (eds): Psoria-sis. New York, Dekker, 1998, pp 421-433.
3. Krueger JG: The immunologic basis for the treatment of psoriasis with new biologic agents. J Am Acad Dermatol 2002; 46: 1-23. (Pubitemid 34073472)
4. Tristani-Firouzi P, Krueger GG: Efficacy and safety of treatment modalities for psoriasis. Cutis 1998; 61:11-21.
5. Goldenberg MM: Etanercept, a novel drug for the treatment of patients with severe, ac-tive rheumatoid arthritis. Clin Ther 1999; 21: 75-87. (Pubitemid 29106691)
6. Goffe B, Cather JC: Etanercept: an overview. J Am Acad Dermatol 2003; 49(suppl 2):S105-S111. (Pubitemid 36951254)
7. Krueger G, Callis K: Potential of tumor ne-crosis factor inhibitors in psoriasis and pso-riatic arthritis. Arch Dermatol 2004; 140: 218-225. (Pubitemid 38500336)
8. Chaudhari U, Romano R, Mulcahy LD, Dooley LT, Baker DG, Gottlieb AB: Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial. Lancet 2001; 357:1842-1847. (Pubitemid 32539117)
9. Gottlieb AB, Evans R, Li S, Dooley LT, Guzzo CA, Baker D, Bala M, Marano CW, Menter A: Infliximab induction therapy for patients with severe plaque-type psoriasis: a random-ized, double-blind, placebo-controlled trial. J Am Acad Dermatol 2004; 51: 534-542. (Pubitemid 39278071)
10. Krueger GG: Selective targeting of T cell sub -sets: focus on alefacept - A remittive therapy for psoriasis. Expert Opin Biol Ther 2002; 2: 431-441. (Pubitemid 34492226)
11. Jenneck C, Novak N: The safety and efficacy of alefacept in the treatment of chronic plaque psoriasis. Ther Clin Risk Manag 2007; 3:411-420. (Pubitemid 47214981)
12. Bresnihan B, Cunnane G: Infection compli-cations associated with the use of biologic agents. Rheum Dis Clin North Am 2003; 29: 185-202. (Pubitemid 36298110)
13. Cunnane G, Doran M, Bresnihan B: Infec-tions and biological therapy in rheumatoid arthritis. Best Pract Res Clin Rheumatol 2003; 17:345-363.
14. Centers for Disease Control and Prevention (CDC): Tuberculosis associated with block-ing agents against tumor necrosis factor-al-pha - California, 2002-2003. MMWR Morb Mortal Wkly Rep 2004; 53: 683-686.
15. Long R, Gardam M: Tumour necrosis factor-alpha inhibitors and the reactivation of latent tuberculosis infection. CMAJ 2003; 168: 1153-1156. (Pubitemid 36543228)
16. Delves PJ, Roitt IM: The immune system. First of two parts. N Engl J Med 2000; 343: 37-49. (Pubitemid 30447991)
17. Lebwohl M, Tyring SK, Hamilton TK, Toth D, Glazer S, Tawfik NH, Walicke P, Dummer W, Wang X, Garovoy MR Pariser D, the Efalizumab Study Group: A novel targeted T-cell modulator, efalizumab, for plaque psoriasis. N Engl J Med 2003; 349: 2004-2013. (Pubitemid 37448923)
18. Kuypers TW, Roos D: Leukocyte membrane adhesion proteins LFA-1, CR3 and p150,95: a review of functional and regulatory aspects. Res Immunol 1989; 140:461-486. (Pubitemid 19200265)
19. Dustin ML, Springer TA: Lymphocyte func-tion-associated antigen-1 (LFA-1) interac-tion with intercellular adhesion molecule-1 (ICAM-1) is one of at least three mechanisms for lymphocyte adhesion to cultured endo-thelial cells. J Cell Biol 1988; 107:321-331.
20. Werther WA, Gonzalez TN, O'Connor SJ, McCabe S, Chan B, Hotaling T, Champe M, Fox JA, Jardieu PM, Berman PW, Presta LG: Humanization of an anti-lymphocyte func-tion-associated antigen (LFA)-1 monoclonal antibody and reengineering of the human-ized antibody for binding to rhesus LFA-1. J Immunol 1996; 157:4986-4995. (Pubitemid 126449577)
21. Jullien D, Prinz JC, Langley RG, Caro I, Dummer W, Joshi A, Dedrick R, Natta P: T-cell modulation for the treatment of chronic plaque psoriasis with efalizumab (Raptiva): mechanisms of action. Dermatology 2004; 208:297-306. (Pubitemid 38736650)
22. Gottlieb A, Krueger JG, Bright R, Ling M, Lebwohl M, Kang S, Feldman S, Spellman M, Wittkowski K, Ochs HD, Jardieu P, Bauer R, White M, Dedrick R Garovoy M: Effects of administration of a single dose of a human-ized monoclonal antibody to CD11a on the immunobiology and clinical activity of pso-riasis. J Am Acad Dermatol 2000; 42:428-435. (Pubitemid 30470349)
23. Papp K, Bissonnette R, Krueger JG, Carey W, Gratton D, Gulliver WP, Lui H, Lynde CW, Magee A, Minier D, Ouellet JP, Patel P, Sha-piro J, Shear NH, Kramer S, Walicke P, Bauer R, Dedrick RL, Kim SS, White M, Garovoy MR: The treatment of moderate to severe psoriasis with a new anti-CD1 la monoclonal antibody. J Am Acad Dermatol 2001; 45:665-674. (Pubitemid 33032561)
24. Gottlieb AB, Krueger JG, Wittkowski K, De-drick R, Walicke PA, Garovoy M: Psoriasis as a model for T cell-mediated disease: immu-nobiologic and clinical effects of treatment with multiple doses of efalizumab, an anti CD11a antibody. Arch Dermatol 2002; 138: 591-600.
25. Gordon KB, Papp KA, Hamilton TK, Walicke PA, Dummer W, Li N, Bresnahan BW, Menter A: Efalizumab for patients with moderate to severe plaque psoriasis: a ran-domized controlled trial. J Am Acad Derma-tol 2003; 290:3073-3080. (Pubitemid 37548113)
26. Lebwohl M, Tyring SK, Hamilton TK, Toth D, Glazer S, Tawfik NH, Walicke P, Dummer W, Wang X, Garovoy MR, Pariser D: A novel targeted T-cell modulator, efalizumab, for plaque psoriasis. N Engl J Med 2003; 349: 2004-2013. (Pubitemid 37448923)
27. Menter A, Gordon K, Carey W, Hamilton T, Glazer S, Caro I, Li N, Gulliver W: Efficacy and safety observed during 24 weeks of efal-izumab therapy in patients with moderate to severe plaque psoriasis. Arch Dermatol 2005; 141:31-38. (Pubitemid 40144437)
28. Pariser DM, Gordon KB, Papp KA, Leonardi CL, Kwon P, Compton PG, Rundle AC, Walicke PA, Lebwohl M: Clinical efficacy of efalizumab in patients with chronic plaque psoriasis: results from three randomized pla-cebo-controlled phase III trials. Part 1. J Cu-tan Med Surg 2005; 9: 303-312. (Pubitemid 44491080)
29. Dubertret L, Sterry W, Bos JD, Chimenti S, Shumack S, Larsen CG, Shear NH, Papp KA, CLE AR Multinational Study Group: Clinical experience acquired with the efalizumab (Raptiva) (CLEAR) trial in patients with moderate-to-severe plaque psoriasis: results from a phase III international randomized, placebo-controlled trial. Br J Dermatol 2006; 155:170-181. (Pubitemid 43876411)
30. Sterry W, Stingl G, Langley RG, Zacharie H, Lahfa M, Giannetti A, Ferrándiz C, Sinclair R Saurat JH, CLEAR Multinational Study Group: Clinical Experience Acquired with Raptiva (CLEAR) trial in patients with mod-erate-to-severe plaque psoriasis: results from extended treatment in an international, phase III, placebo-controlled trial. J Dtsch Dermatol Ges 2006; 4: 947-956.
31. Leonardi CL, Papp KA, Gordon KB, Menter A, Feldman SR, Caro I, Walicke PA, Comp-ton PG, Gottlieb AB, Efalizumab Study Group: Extended efalizumab therapy im-proves chronic plaque psoriasis: results from a randomized phase III trial. J Am Acad Der-matol 2005; 52:425-433.
32. Gottlieb AB, Hamilton T, Caro I, Kwon P, Compton PG, Leonardi CL, Efalizumab Study Group: Long-term continuous efali-zumab therapy in patients with moderate to severe chronic plaque psoriasis: updated re-sults from an ongoing trial. J Am Acad Der-matol 2006; 54(suppl 1):S154-S163. (Pubitemid 43238298)
33. Menter A, Leonardi CL, Sterry W, Bos JD, Papp KA: Long-term management of plaque psoriasis with continuous efalizumab thera-py. J Am Acad Dermatol 2006; 54(suppl 1): S182-188. (Pubitemid 43238301)
34. Fredriksson T, Pettersson U: Severe psoria-sis - Oral therapy with a new retinoid. Der-matologica 1978; 157:238-244. (Pubitemid 8387357)
35. Menter A, Hamilton TK, Toth DP, Leung HM, Wetherill G, Hennessey B, Garovoy M, Kwon P, Pariser DM, Efalizumab Study Group: Transitioning patients from efali-zumab to alternative psoriasis therapies: findings from an open-label, multicenter, Phase IIIb study. Int J Dermatol 2007; 46: 637-648. (Pubitemid 46915260)